{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:16:55Z","timestamp":1788963415998,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autologous stem cell transplantation (auto-SCT) remains an important pillar in multiple myeloma (MM) therapy; however, there is an increased risk of developing second primary malignancy including second hematological malignancy (SHM). We performed a retrospective study of patients with MM who underwent an auto-SCT at our institution between 1990 and 2022 and subsequently developed SHM. Among 3401 patients with MM who underwent auto-SCT, 110 (3.2%) developed SHM [therapy related myeloid neoplasm (t-MN)\u2009=\u200998; acute B cell lymphoblastic leukemia (t-B-ALL)\u2009=\u200911 and mixed phenotype acute leukemia=1). The cumulative incidence of SHM has increased between the pre-novel (auto-SCT, 1990\u20132006) and novel agent eras (2007- 2022) (1.1% vs 2.0% at 60 months;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.03). Somatic mutations in\n                    <jats:italic>TP 53<\/jats:italic>\n                    gene were seen in 40% of patients with t-MN. Among t-B-ALL patients, high incidence of hypodiploidy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094) and\n                    <jats:italic>IKZF1<\/jats:italic>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093) deletion was observed. In multivariate analysis, receiving an alkylator based induction, radiation therapy, achieving a complete response after auto-SCT, use of cyclophosphamide for stem cell mobilization and lenalidomide maintenance were independent predictors of developing SHM. Patients with MM who developed a SHM had an inferior overall survival (OS). Given the median OS for MM continues to improve, monitoring for SHM and risk mitigation strategies is crucial.\n                  <\/jats:p>","DOI":"10.1038\/s41408-026-01537-4","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:55:12Z","timestamp":1782237312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Binoy","family":"Yohannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Langworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-901X","authenticated-orcid":false,"given":"Lindsey E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma M.","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S.Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasiya","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-3380","authenticated-orcid":false,"given":"Hefazi","family":"Torghabeh M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","volume":"108","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, et al. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023;108:3384\u201391. https:\/\/doi.org\/10.3324\/haematol.2023.282905.","journal-title":"Haematologica"},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/ijc.33135","volume":"147","author":"Y Usui","year":"2020","unstructured":"Usui Y, Ito H, Koyanagi Y, Shibata A, Matsuda T, Katanoda K, et al. Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study. Int J Cancer. 2020;147:3102\u20139. https:\/\/doi.org\/10.1002\/ijc.33135.","journal-title":"Int J Cancer"},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.13439","volume":"105","author":"M Mohty","year":"2020","unstructured":"Mohty M, Knauf W, Romanus D, Corman S, Verleger K, Kwon Y, et al. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. Eur J Haematol. 2020;105:308\u201325. https:\/\/doi.org\/10.1111\/ejh.13439.","journal-title":"Eur J Haematol"},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.21037\/tcr-24-1721","volume":"14","author":"N Dong","year":"2025","unstructured":"Dong N, Ye B, Liu S. Investigating additional malignancy rates and prognostic factors in multiple myeloma patients: a Surveillance, Epidemiology, and End Results (SEER) database retrospective cohort study. Transl Cancer Res. 2025;14:2192\u2013206. https:\/\/doi.org\/10.21037\/tcr-24-1721.","journal-title":"Transl Cancer Res"},{"key":"1537_CR6","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","volume":"118","author":"S Mailankody","year":"2011","unstructured":"Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118:4086\u201392. https:\/\/doi.org\/10.1182\/blood-2011-05-355743.","journal-title":"Blood"},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2013.34","volume":"27","author":"LE Roeker","year":"2013","unstructured":"Roeker LE, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17\u2009315 patients. Leukemia. 2013;27:1391\u20133. https:\/\/doi.org\/10.1038\/leu.2013.34.","journal-title":"Leukemia"},{"key":"1537_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.1987.107","volume":"55","author":"J Cuzick","year":"1987","unstructured":"Cuzick J, Erskine S, Edelman D, Galton D. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer. 1987;55:523\u20139. https:\/\/doi.org\/10.1038\/bjc.1987.107.","journal-title":"Br J Cancer"},{"key":"1537_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archinte.1975.00330010187024","volume":"135","author":"RA Kyle","year":"1975","unstructured":"Kyle RA. Multiple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med. 1975;135:185 https:\/\/doi.org\/10.1001\/archinte.1975.00330010187024.","journal-title":"Arch Intern Med"},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(13)70609-0.","journal-title":"Lancet Oncol"},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","volume":"7","author":"BK Ragon","year":"2023","unstructured":"Ragon BK, Shah MV, D\u2019Souza A, Estrada-Merly N, Gowda L, George G, et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023;7:2746\u201357. https:\/\/doi.org\/10.1182\/bloodadvances.2022009138.","journal-title":"Blood Adv"},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jha2.680","volume":"4","author":"MO Ali","year":"2023","unstructured":"Ali MO, Abdullah HM, Obeidat K, Chakraborty R, Al Hadidi S. Follow up duration of phase III multiple myeloma clinical trials: a systematic review. EJHaem. 2023;4:719\u201322. https:\/\/doi.org\/10.1002\/jha2.680.","journal-title":"EJHaem"},{"key":"1537_CR13","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365. https:\/\/doi.org\/10.1182\/blood-2012-03-420489.","journal-title":"Blood"},{"key":"1537_CR14","doi-asserted-by":"publisher","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence 2022;1. https:\/\/doi.org\/10.1056\/EVIDoa2200008.","DOI":"10.1056\/EVIDoa2200008"},{"key":"1537_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41409-024-02455-4","volume":"60","author":"O Elghawy","year":"2025","unstructured":"Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, et al. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplant. 2025;60:64\u20138. https:\/\/doi.org\/10.1038\/s41409-024-02455-4.","journal-title":"Bone Marrow Transplant"},{"key":"1537_CR17","doi-asserted-by":"publisher","first-page":"205.e1","DOI":"10.1016\/j.jtct.2023.06.015","volume":"30","author":"FF Yalniz","year":"2024","unstructured":"Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, et al. Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation. Transplant Cell Ther. 2024;30:205.e1\u2013205.e12. https:\/\/doi.org\/10.1016\/j.jtct.2023.06.015.","journal-title":"Transplant Cell Ther"},{"key":"1537_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101144","volume":"33","author":"K Maclachlan","year":"2020","unstructured":"Maclachlan K, Diamond B, Maura F, Hillengass J, Turesson I, Landgren CO, et al. Second malignancies in multiple myeloma; emerging patterns and future directions. Best Pract Res Clin Haematol. 2020;33:101144. https:\/\/doi.org\/10.1016\/j.beha.2020.101144.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1537_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41375-023-01864-6","volume":"37","author":"D Moreno Berggren","year":"2023","unstructured":"Moreno Berggren D, Garelius H, Willner Hjelm P, Nilsson L, Rasmussen B, Weibull CE, et al. Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. Leukemia. 2023;37:1103\u201312. https:\/\/doi.org\/10.1038\/s41375-023-01864-6.","journal-title":"Leukemia"},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","volume":"56","author":"M Jentzsch","year":"2021","unstructured":"Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, et al. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56:936\u201345. https:\/\/doi.org\/10.1038\/s41409-020-01129-1.","journal-title":"Bone Marrow Transplant"},{"key":"1537_CR21","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679.","journal-title":"J Clin Oncol"},{"key":"1537_CR22","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1182\/blood-2012-11-466961","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013;121:4753\u20137. https:\/\/doi.org\/10.1182\/blood-2012-11-466961.","journal-title":"Blood"},{"key":"1537_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJM197910043011402","volume":"301","author":"DE Bergsagel","year":"1979","unstructured":"Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743\u20138. https:\/\/doi.org\/10.1056\/NEJM197910043011402.","journal-title":"N Engl J Med"},{"key":"1537_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","volume":"95","author":"R Govindarajan","year":"1996","unstructured":"Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349\u201353. https:\/\/doi.org\/10.1046\/j.1365-2141.1996.d01-1891.x.","journal-title":"Br J Haematol"},{"key":"1537_CR25","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","volume":"57","author":"RM Rifkin","year":"2016","unstructured":"Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, et al. Connect MM\u00ae - the multiple myeloma disease registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016;57:2228\u201331. https:\/\/doi.org\/10.3109\/10428194.2015.1132419.","journal-title":"Leuk Lymphoma"},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jnci\/djj001","volume":"98","author":"LB Travis","year":"2006","unstructured":"Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15\u201325. https:\/\/doi.org\/10.1093\/jnci\/djj001.","journal-title":"J Natl Cancer Inst"},{"key":"1537_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"A Berrington de Gonzalez","year":"2011","unstructured":"Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(11)70061-4.","journal-title":"Lancet Oncol"},{"key":"1537_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01154-z","volume":"14","author":"P-M Morice","year":"2024","unstructured":"Morice P-M, Khalife-Hachem S, Sassier M, Lelong-Boulouard V, Danu A, Pasquier F, et al. Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO\u2019s pharmacovigilance database. Blood Cancer J. 2024;14:177. https:\/\/doi.org\/10.1038\/s41408-024-01154-z.","journal-title":"Blood Cancer J"},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/bloodadvances.2022007496","volume":"7","author":"EK Barnell","year":"2023","unstructured":"Barnell EK, Skidmore ZL, Newcomer KF, Chavez M, Campbell KM, Cotto KC, et al. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Adv. 2023;7:236\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2022007496.","journal-title":"Blood Adv"},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135. https:\/\/doi.org\/10.1126\/science.1244851.","journal-title":"Science"},{"key":"1537_CR31","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1182\/bloodadvances.2022009212","volume":"7","author":"MB Geyer","year":"2023","unstructured":"Geyer MB, Shaffer BC, Bhatnagar B, Mims AS, Klein V, Dilip D, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023;7:3087\u201398. https:\/\/doi.org\/10.1182\/bloodadvances.2022009212.","journal-title":"Blood Adv"},{"key":"1537_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2204925.","journal-title":"N Engl J Med"},{"key":"1537_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable residual disease\u2013guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393:425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2505133.","journal-title":"N Engl J Med"},{"key":"1537_CR34","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1114138.","journal-title":"N Engl J Med"},{"key":"1537_CR35","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","volume":"9","author":"K Saleem","year":"2022","unstructured":"Saleem K, Franz J, Klem MLou, Yabes JG, Boyiadzis M, Jones JR, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022;9:e906\u201318. https:\/\/doi.org\/10.1016\/S2352-3026(22)00289-7.","journal-title":"Lancet Haematol"},{"key":"1537_CR36","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood.2021014956","volume":"140","author":"AS Sperling","year":"2022","unstructured":"Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753\u201363. https:\/\/doi.org\/10.1182\/blood.2021014956.","journal-title":"Blood"},{"key":"1537_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170. https:\/\/doi.org\/10.1038\/s41408-024-01156-x.","journal-title":"Blood Cancer J"},{"key":"1537_CR38","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901. https:\/\/doi.org\/10.1016\/S2352-3026(23)00236-3.","journal-title":"Lancet Haematol"},{"key":"1537_CR39","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1182\/blood.2024027686","volume":"145","author":"E Terpos","year":"2025","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145:2353\u201360. https:\/\/doi.org\/10.1182\/blood.2024027686.","journal-title":"Blood"},{"key":"1537_CR40","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8009\u20138009. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8009.","journal-title":"J Clin Oncol"},{"key":"1537_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"key":"1537_CR42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","volume":"10","author":"M Gurney","year":"2024","unstructured":"Gurney M, Baranwal A, Rosenthal A, Kharfan-Dabaja MA, Kenderian SS, Lin Y, et al. Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 2024;10:532 https:\/\/doi.org\/10.1001\/jamaoncol.2023.7182.","journal-title":"JAMA Oncol"},{"key":"1537_CR43","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5:2982\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021004554.","journal-title":"Blood Adv"},{"key":"1537_CR44","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/bloodadvances.2025015981","volume":"9","author":"JN Gustine","year":"2025","unstructured":"Gustine JN, Branagan AR, Cirstea DD, Rexha F, Han R, Yee AJ, et al. Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Adv. 2025;9:3026\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2025015981.","journal-title":"Blood Adv"},{"key":"1537_CR45","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390:2047\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2401361.","journal-title":"N Engl J Med"},{"key":"1537_CR46","doi-asserted-by":"publisher","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2025:JCO2500760. https:\/\/doi.org\/10.1200\/JCO-25-00760.","DOI":"10.1200\/JCO-25-00760"},{"key":"1537_CR47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/blood.2024026236","volume":"146","author":"M Lionetti","year":"2025","unstructured":"Lionetti M, Scopetti M, Matera A, Maeda A, Marella A, Lazzaroni F, et al. Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes. Blood. 2025;146:571\u201384. https:\/\/doi.org\/10.1182\/blood.2024026236.","journal-title":"Blood"},{"key":"1537_CR48","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/s41375-024-02258-y","volume":"38","author":"H Awada","year":"2024","unstructured":"Awada H, Gurnari C, Visconte V, Durmaz A, Kuzmanovic T, Awada H, et al. Clonal hematopoiesis\u2013derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders. Leukemia. 2024;38:1266\u201374. https:\/\/doi.org\/10.1038\/s41375-024-02258-y.","journal-title":"Leukemia"},{"key":"1537_CR49","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood.2022018244","volume":"141","author":"B Diamond","year":"2023","unstructured":"Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141:2359\u201371. https:\/\/doi.org\/10.1182\/blood.2022018244.","journal-title":"Blood"},{"key":"1537_CR50","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/bloodadvances.2019001157","volume":"4","author":"JF Soerensen","year":"2020","unstructured":"Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020;4:885\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2019001157.","journal-title":"Blood Adv"},{"key":"1537_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16805-5","volume":"11","author":"TH Mouhieddine","year":"2020","unstructured":"Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996. https:\/\/doi.org\/10.1038\/s41467-020-16805-5.","journal-title":"Nat Commun"},{"key":"1537_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/2643-3230.BCD-24-0274","volume":"6","author":"C Guerrero","year":"2025","unstructured":"Guerrero C, Larrayoz M-J, Erdozain I, Puig N, Cedena M-T, Maia C, et al. Dynamics of mutant hematopoietic progenitor cells are not associated with clinical outcomes in multiple myeloma. Blood Cancer Discov. 2025;6:203\u201316. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0274.","journal-title":"Blood Cancer Discov"},{"key":"1537_CR53","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3324\/haematol.2018.193599","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Stiller T, Tsai N-C, Song JY, Cao T, Bandara NA, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103:1662\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.193599.","journal-title":"Haematologica"},{"key":"1537_CR54","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","volume":"3","author":"C Saygin","year":"2019","unstructured":"Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3:4228\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2019000925.","journal-title":"Blood Adv"},{"key":"1537_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41409-024-02462-5","volume":"60","author":"K Raj","year":"2025","unstructured":"Raj K, Eikema D-J, Lawless S, Koster L, Kunadt D, Kr\u00f6ger N, et al. Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2025;60:220\u20136. https:\/\/doi.org\/10.1038\/s41409-024-02462-5.","journal-title":"Bone Marrow Transplant"},{"key":"1537_CR56","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18154","volume":"197","author":"H Tariq","year":"2022","unstructured":"Tariq H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, Segal J, Gurbuxani S, et al. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022;197:736\u201344. https:\/\/doi.org\/10.1111\/bjh.18154.","journal-title":"Br J Haematol"},{"key":"1537_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjh.15426","volume":"182","author":"LJ Costa","year":"2018","unstructured":"Costa LJ, Godby KN, Chhabra S, Cornell RF, Hari P, Bhatia S. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. Br J Haematol. 2018;182:513\u201320. https:\/\/doi.org\/10.1111\/bjh.15426.","journal-title":"Br J Haematol"},{"key":"1537_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00400-4","volume":"11","author":"AS Rosenberg","year":"2021","unstructured":"Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Hoeg R, Wun T, et al. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021;11:5. https:\/\/doi.org\/10.1038\/s41408-020-00400-4.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01537-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:05:03Z","timestamp":1788782703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01537-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01537-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MAG: Honoraria\n                      :\n                      Celgene, Med Learning Group, Research to Practice, Prothena, Apellis Pharmaceuticals, Amgen, AbbVie, Akcea Therapeutics, Sanofi, Telix Pharmaceuticals, Janssen Oncology, Juno\/Celgene, Alnylam. Consulting or Advisory Role: Prothena, Bristol Myers Squibb\/Sanofi. Travel, Accommodations, Expenses: Prothena, Celgene, Novartis. AD: Consulting or Advisory Role: Janssen Research & Development. Research Funding: Celgene (Inst), Janssen Oncology (Inst), Pfizer (Inst), Takeda (Inst), Alnylam (Inst), Prothena. Travel, Accommodations, Expenses: Pfizer, Janssen Oncology, Prothena. PK: Honoraria: Pharmacyclics, Sanofi (Inst), BeiGene, MustangBio, AstraZeneca, AbbVie (Inst). Consulting or Advisory Role: Sanofi (Inst). Research Funding: Amgen (Inst), Takeda (Inst), Sanofi (Inst), AbbVie (Inst), GlaxoSmithKline (Inst), Sorrento Therapeutics (Inst), Karyopharm Therapeutics (Inst), Regeneron (Inst), Ichnos Sciences (Inst), Bristol Myers Squibb\/Celgene (Inst). DD: Consulting for Alexion (AstraZeneca), Apellis, Bristol Myers Squibb, Genentech\/Roche, Janssen, Legend Biotech, Novartis, Ossium Health, Sanofi, and Sorrento Therapeutics. Research support from K36 Therapeutics. NL: Takeda (Membership on an entity\u2019s Board of Directors or advisory committees). WIG: Consulting or Advisory Role: Amgen (Inst). Research Funding: ORIC Pharmaceuticals (Inst), Bristol Myers Squibb Foundation (Inst). Patents, Royalties, Other Intellectual Property: Patent number: 10996224: Assessing and treating precursor plasma cell disorders. TK: Novartis (Research Funding). JMC: Stock and Other Ownership Interests: Geron. YL: Bluebird Bio, Celgene, Janssen, Kite (Consultancy and Research Funding), Gamida Cell, Novartis, Juno, Legend, Sorrento, Vineti (Consultancy), Merck, Takeda (Research Funding), Abbvie, Celgene, Janssen, Takeda, Adaptive, MedImmune\/Astra Zeneca (Membership on an entity\u2019s Board of Directors or advisory committees), Kite, Merck, Novartis, Roche, Sanofi (Research Funding), Oncopeptides (Independent review committee). SVR: Honoraria: Research to Practice, Medscape. Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date. SK: Consulting or Advisory Role: Takeda (Inst), Janssen Oncology (Inst), Genentech\/Roche (Inst), AbbVie (Inst), Bristol Myers Squibb\/Celgene (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), K36 (Inst). Research Funding: Takeda (Inst), AbbVie (Inst), Novartis (Inst), Sanofi (Inst), Janssen Oncology (Inst), MedImmune (Inst), Roche\/Genentech (Inst), CARsgen Therapeutics (Inst), Allogene Therapeutics (Inst), GlaxoSmithKline (Inst), Regeneron (Inst), Bristol Myers Squibb\/Celgene (Inst). Travel, Accommodations, Expenses: AbbVie, Pfizer. EM: consultation fee from Protego (fee paid to the institution). The remaining authors declare no competing interests. MVS: receives research funding to the institution from Astellas, Celgene, and Marker Therapeutics. MMP: received research funding from Kura Oncology, Stemline Therapeutics, Epigenetix, Solutherapeutics, and Polaris and has served on the advisory board for AstraZeneca and SOBI Pharmaceuticals. AAK\n                      :\n                      provides research support to Novartis and Astex.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Approval obtained from Mayo Clinic IRB (#\n                      \n                      ). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"148"}}